Apex is a Phase 2 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in people with Advanced Systemic Mastocytosis (AdvSM).
LEARN MORE
Summit is a Phase 2 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in people with Nonadvanced Systemic Mastocytosis (NonAdvSM).
LEARN MORE
Peak is a Phase 3 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in combination with sunitinib vs. sunitinib alone, in people with Gastrointestinal Stromal Tumors (GIST).
LEARN MOREBelow are some frequently asked questions about the clinical trials:
Cogent Biosciences, Inc. is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.
Millions of people around the world are living with a genetically defined disease. Genetically defined diseases are diseases in which specific genetic mutations are known to cause disease, and can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases. For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.
Please explore our website to find out more.
